Literature DB >> 10488058

Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection.

M A Opavsky1, J Penninger, K Aitken, W H Wen, F Dawood, T Mak, P Liu.   

Abstract

Viral myocarditis is an important cause of heart failure and dilated cardiomyopathy. T lymphocytes are implicated in myocardial damage in murine models of coxsackievirus B3 (CVB3) myocarditis. We used knockout mice lacking CD4 (CD4(-/-)), CD8 (CD8(-/-)), both coreceptors (CD4(-/-)CD8(-/-)), or the T-cell receptor beta chain (TCRbeta(-/-)) to address the contribution of T-cell subpopulations to host susceptibility to CVB3 myocarditis. Severity of disease was magnified in CD8(-/-) mice but attenuated in CD4(-/-) mice, consistent with a pathogenic role for CD4(+) lymphocytes. Elimination of both CD4 and CD8 molecules from T lymphocytes by genetic knockout better protected mice from myocarditis, demonstrating that both CD4(+) and CD8(+) T cells contribute to host susceptibility. The same benefit occurred in TCRbeta(-/-) mice, with prolonged survival and minimal myocardial disease observed after CVB3 infection. Elevated interferon-gamma and decreased tumor necrosis factor-alpha expression are associated with attenuated myocardial damage in CD4(-/-)CD8(-/-) mice. These results show that the presence of TCRalphabeta(+) T cells enhances host susceptibility to myocarditis. The severity of myocardial damage and associated mortality are dependent on the predominant T-cell type available to respond to CVB3 infection. One mechanism by which CD4(+) and CD8(+) T-cell subsets influence the pathogenesis of myocarditis may involve specific cytokine expression patterns.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488058     DOI: 10.1161/01.res.85.6.551

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  44 in total

1.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

2.  Absence of viral nucleic acids in early and late dilated cardiomyopathy.

Authors:  N G Mahon; B Zal; G Arno; P Risley; J Pinto-Basto; W J McKenna; M J Davies; C Baboonian
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

3.  Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders.

Authors:  Gudrun Szalay; Martina Sauter; Joachim Hald; Andreas Weinzierl; Reinhard Kandolf; Karin Klingel
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 4.  Immune cell diversity contributes to the pathogenesis of myocarditis.

Authors:  Xiumeng Hua; Jiangping Song
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 5.  Type B coxsackieviruses and their interactions with the innate and adaptive immune systems.

Authors:  Christopher C Kemball; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

6.  Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice.

Authors:  Carola Leipner; Katja Grün; Ilka Schneider; Brigitte Glück; Holger H Sigusch; Axel Stelzner
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

Review 7.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 8.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

Review 9.  An approach to the treatment of pediatric myocarditis.

Authors:  Daniel Levi; Juan Alejos
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis.

Authors:  Mary Anne Opavsky; Tami Martino; Marlene Rabinovitch; Josef Penninger; Chris Richardson; Martin Petric; Cathy Trinidad; Lisa Butcher; Janice Chan; Peter P Liu
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.